3.34
3.34 (0%)
As of Feb 14, 2025
Aptevo Therapeutics Inc. [APVO]
Source:
Company Overview
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and three preclinical candidates currently in development.
| Country | United States |
| Headquarters | seattle, washington |
| Phone Number | (206) 838-0500 |
| Industry | manufacturing |
| CEO | Marvin L. White |
| Website | www.aptevotherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-24.6 |
| Net Income | $-24.1 |
| Net Cash | $-8.2 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -119.4% |
| Profit as % of Stockholder Equity | -507.5% |
Management Effectiveness
| Return on Equity | -507.5% |
| Return on Assets | -154.8% |
| Turnover Ratio | |
| EBITA | $-24.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $15.6 |
| Total Liabilities | $10.8 |
| Operating Cash Flow | $-23.8 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $15.6 |
